In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on Achieve Life Sciences (ACHV), with a price target of $2.00. The company’s shares closed last Monday at $0.56, close to its 52-week low of $0.46.
According to TipRanks.com, McCarthy is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -4.8% and a 31.6% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group, Hancock Jaffe Laboratories, and Lineage Cell Therapeutics.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Achieve Life Sciences with a $6.00 average price target.
Based on Achieve Life Sciences’ latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $3.67 million. In comparison, last year the company had a GAAP net loss of $3.64 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Achieve Life Sciences, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of cytisinicline for smoking cessation. Its products, cytisine, is a plant-based alkaloid with a binding affinity to the nicotinic acetylcholine receptor.